We herein analyzed the relationships among the immunohistochemical expression of alpha-enolase (ENO1) and clinicopathological factors in order to define the significance of ENO1 in lung adenocarcinomas (ADCs). ENO1 expression was detected in most of the ADCs examined (95.8%), but not in bronchial and alveolar epithelia. ENO1 expression was typically observed in the cytoplasm among most ADCs (95.8%), but was also detected in the nucleus (56.3%). The levels were significantly higher in terminal respiratory unit (TRU) cytological subtype ADCs. Neither cytoplasmic nor nuclear expression was associated with any other clinicopathological factors including postoperative survival and growth activity. These results suggest that ENO1 is a crucial factor promoting neoplastic transformation exclusively in TRU subtype ADCs. We also investigated the potential utility of the immunohistochemical expression of ENO1 to differentiate TRU-type ADC cells from the reactive hyperplasia of pneumocytes and bronchiolar epithelial cells because difficulties are associated with discriminating these lesions in small biopsy specimens. The sensitivity and specificity of ENO1 (cytoplasmic/ nuclear) were 87.5%/37.5% and 88.9%/100%, respectively, which are superior to those of p53 (18.8% and 100%). ENO1 has potential as a biomarker to assist in the histopathological detection of TRU subtype ADC cells.
Lung cancer is one of the most common causes of cancerrelated death in the developed world.
1,2 Adenocarcinoma (ADC) is the most common histological type among lung cancers. A deeper understanding of the pathological basis of lung ADC is important for improving clinical performance. We previously identified important molecules involved in lung carcinogenesis through a comprehensive search for downstream targets of KRAS, the most common oncogene. [3] [4] [5] The downstream targets of the KRAS oncogene were found to be essential not only in KRAS-mediated carcinogenesis, but also in EGFR-and other unknown potential oncogene-mediated lung carcinogenesis. [3] [4] [5] Thus, different driver oncogenes have been suggested to activate a common signaling pathway to promote carcinogenesis. [6] [7] [8] Studies on the downstream targets of the KRAS oncogene are considered to be a useful strategy for elucidating the common important molecular bases of lung cancers. Among the downstream targets identified in our recent study, 3 we focus here on alpha-enolase (ENO1) because it was also found to be a target of c-MYC, another essential oncogene, [9] [10] [11] and our preliminary examination revealed the strong expression of ENO1 in lung ADCs. ENO1 is a multifunctional protein. It acts as a dehydrase that localizes in cytoplasm and catalyzes the conversion of 2-phospho-D-glycerate to phosphoenolpyruvate in the final step of the glycolytic pathway in order to maintain aerobic glycolysis. 12 The ENO1 gene may also be alternatively translated into the c-MYC promoter-binding protein (MBP-1), which lacks a part of the amino-terminal residues of ENO1, localizes in the nucleus, and acts as a transcription repressor for the c-MYC oncogene. 13 ENO1 is also expressed on the cell surface, on which it acts as a plasminogen receptor and contributes to cell invasion and metastasis. [9] [10] [11] 14, 15 ENO1 was previously reported to be up-regulated at the mRNA and/or protein level in several tumors including breast, lung, prostatic, and pancreatic cancers, and to be transcriptionally regulated by RAS, MYC, and HIF-1 alpha. 10, 11, 14, 15 ENO1 also functions as a tumor-associated antigen that induces a humoral and/or cellular autoimmune response that targets neoplastic cells in cancer patients. 9 Thus, ENO1 may be an important molecule in cancer development that may also act as a therapeutic target. However, the potential relationships among the expression of ENO1 and clinicopathological factors in lung ADCs have not yet been investigated in detail.
We herein examine the immunohistochemical expression of ENO1 in surgically resected primary lung ADCs, and analyzed the relationships among its expression levels and clinicopathological factors in order to elucidate the significance of ENO1 in lung ADCs. We also verified its potential utility in a histopathological diagnosis.
MATERIALS AND METHODS

Primary lung cancer
A total of 142 ADCs that were removed by radical surgical resection at the Kanagawa Prefectural Cardiovascular and Respiratory Center (Yokohama, Japan) were examined. Twenty biopsy specimens were also from the Kanagawa Prefectural Cardiovascular and Respiratory Center. The histological subtypes of ADCs were assessed according to the WHO tumor classification system. 16, 17 Cytological subtype (terminal respiratory unit (TRU), non-TRU/bronchiolar surface epithelium (BSE), or unclassifiable) was determined 
0." Levels equal to/more than 0.5 (less than 0.5) were judged as "high (low)." The nuclear labeling indices of ENO1 were calculated as the proportion of nuclei showing unequivocally intense signals. The ENO1 nuclear labeling index equal to/more than 0.5 (less than 0.5) was judged as "high (low)." The labeling indices of Ki-67 were also calculated as the proportion of strongly positive nuclei. The Ki-67 labeling indices of <10% and !10% were classified as low and high levels according to previous studies.
20
P53 expression was judged as "positive" if nuclei showing unequivocally intense signals were diffusely observed. 21 
Search for KRAS and EGFR gene mutations
The tumorous part was dissected from formalin-fixed, paraffin-embedded tissue sections. DNA was purified using the conventional phenol/chloroform extraction method. Mutations in the KRAS oncogene (exons 2 and 3) and EGFR oncogene (exons 18, 19, 20, and 21) were analyzed by direct sequencing according to a method described elsewhere.
5,22
Statistical analysis
The relationships among immunohistochemical expression and clinicopathological factors were analyzed by the chisquared test. Recurrence curves were plotted using the Kaplan-Meier method, and the absolute risk of recurrence at five years was estimated from these curves. Differences in disease-free survival or recurrent-free survival were analyzed using the Log-rank test. P values less than 0.05 were considered to be significant.
RESULTS
Expression of ENO1 in lung ADCs
The immunohistochemical expression of ENO1 was detected in 95.8% (136/142) of the ADCs examined, but not in non-neoplastic bronchial and alveolar epithelia under a healthy physiological state (Fig. 1) . Lung ADC cells typically expressed ENO1 in the cytoplasm (Fig. 1 ), but also often expressed it in the nucleus (Fig. 1) . The nuclear expression of ENO1 was detected in 56.3% (80/142) of ADCs.
Relationships among ENO1 expression and clinicopathological factors
ENO1 expression levels were evaluated separately in cytoplasm and nucleus according to the scoring system described in the Materials and Methods section. High cytoplasmic and nuclear expression levels correlated with TRU subtype ADCs (Fig. 2 , Tables 1 and 2 ). Neither cytoplasmic nor nuclear expression associated with any of the other clinicopathological factors including age, gender, smoking history, tumor size, lymph node metastasis, histological subtypes, driver mutation types, growth activity (Tables 1  and 2 ), or post-operative outcomes (supporting information Fig. S1 ).
The potential utility of ENO1 expression in histopathological diagnoses
As described above, most of the ADCs examined were positive for ENO1 immunohistochemical expression, whereas bronchial and alveolar epithelia were typically negative.
These results suggest the potential diagnostic utility of the immunohistochemical expression of ENO1. The expression of both cytoplasmic and nuclear ENO1 was almost constantly detected in all the subtypes (Table 3 ). The frequency of p53 expression, a conventional diagnostic marker, 23 was particularly lower in lepidic and papillary subtypes (Table 3) , as has been documented. 24, 25 These results suggest the advantage of ENO1 expression as a marker for detecting lung ADC cells of lepidic and papillary subtypes. Among the series of biopsy specimens in our faculty (the Kanagawa Prefectural Cardiovascular and Respiratory Center), cases suspected of being malignant, but difficult Fequencies (%) of the paremeters between the high and low expressors among the different subjects are shown. Levels of cytoplasmic ENO1 expression equal to/more than 0.5 (less than 0.5) were judged as "high (low)." PYI, pack year index; TRU, terminal respiratory unit; BSE, bronchial surface epithelium; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma. () indicates sample size.
to define due to the small number of cells or very slight morphological changes, were selected ( Table 4) . Most of these cases were the lepidic or papillary subtype of ADCs. We evaluated the diagnostic utility of either either cytoplasmic or nuclear ENO1 expression in these cases and compared it with that of p53 expression (Table 4) . Some representative results of immunohistochemistry for ENO1 and p53 in cases of ADC and reactive hyperplasia are shown (Fig. 3) . The sensitivity and specificity of ENO1 (cytoplasmic/nuclear) were 87.5%/37.5% and 88.9%/100%, while those of p53 were 18.8% and 100%. Fequencies (%) of the paremeters between the high and low expressors among the different subjects are shown. Levels of cytoplasmic ENO1 expression equal to/more than 0.5 (less than 0.5) were judged as "high" ("low"). PYI, pack year index; TRU, terminal respiratory unit; BSE, bronchial surface epithelium; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma. () indicates sample size. Table 4 Immunohistochemical expression of cytoplasmic ENO1, nuclear ENO1, and p53 in lung lesions difficult to be defined by biopsy examinations.
Case
Tentative diagnosis on biopsy specimens
Final diagnosis on resected specimens cENO1 nENO1 p53
No neoplasm, Asper. Organ.
---cENO1, cytoplasmic ENO1; nENO1, nuclear ENO1; þ, positive; -, negative. Unequivocally strong immunohistochemical signals observed were judged as "positive." ADC, adenocarcinoma; NTM, non-tuberculosis mycobacterium infection; TBC, tuberculosis infection; Asper., aspergillosis; Organ., organizing pneumonia.
DISCUSSION
The present study focused on ENO1 and investigated the significance of its expression in lung ADCs. Overall, the immunohistochemical expression of ENO1 was detected in most of the ADCs examined, but not in non-neoplastic airway epithelia. High ENO1 expression levels were predominantly detected in TRU cytological subtype ADCs and even in low-grade tumors (lepidic and papillary histological subtypes). These results suggest that the up-regulated expression of ENO1 is crucial for neoplastic transformation during the early stage of carcinogenesis and may play an important role in TRU subtype ADCs. The strong activation of the anabolic system through aerobic glycolysis, in which ENO1 participates, is essential to cancer cell growth. 9, 10 This event is known as the "Warburg effect." 12 The upregulated expression of ENO1 has been demonstrated in various types of malignant neoplasms including lung cancers. 26, 27 Our results are consistent with these findings.
ENO1 is a multifunctional protein. A transcriptional variant of ENO1, which is known as MBP-1 and expressed in nuclei, acts as a transcriptional repressor of the c-MYC oncogene and other cancer-related molecules in order to modulate cell growth and death. 13 The nuclear expression of ENO1 was consistently detected in the present study. It was predominantly observed in the TRU subtype of ADCs with low-grade (lepidic and papillary) histological features. A previous study demonstrated that c-MYC oncogene amplification (gene copy number gain) was an early event in lung carcinogenesis, and was detected in 11.0% (7/58) of non-invasive lung ADCs. 28 Nuclear ENO1 (MBP-1) is assumed to repress amplified c-MYC activity during early carcinogenesis in order to interfere with cancer progression. The relationship between c-MYC gene copy numbers and nuclear ENO1 expression levels warrants further study in order to define the role of nuclear ENO1 in lung carcinogenesis. On the other hand, ENO1 is also expressed on the cell surface, on which it acts as a plasminogen receptor and contributes to cell invasion and metastasis. [9] [10] [11] 14, 15 In the present study, no significant relationship was observed among ENO1 levels, lymph node metastasis, and tumor recurrence. ENO1 is multifunctional and its role in carcinogenesis appears to be complex. The sum of these different functions affects the pathobiological properties of neoplastic cells. Thus, difficulties are associated with confirming the relationships among the simple immunohistochemical expression of ENO1 and specific clinicopathological features. Comprehensive analyses of the different functions of ENO1 may be necessary in order to define its clinicopathological significance.
Aside from the biological role of ENO1 in carcinogenesis, a previous study reported that high ENO1 immunohistochemical expression levels were associated with worse outcomes among patients with lung cancers. 27 However, our results failed to confirm this relationship. This discrepancy may be due to differences in (i) analytical subjects, (ii) the specificities of antibodies (the monoclonal antibody clone EPR10864 (B) in our study, and a polyclonal antibody that was originally generated by Chang et al. in the previous study), and (iii) the judgment system for immunohistochemical expression. In analytical subjects, the present study exclusively examined ADCs at stage I (117 cases), whereas the previous study by Chang et al. 27 examined non-small cell carcinomas mixing squamous cell carcinomas and ADCs at different stages (a total of 80 cases). The present study is the first to investigate the actual relationship between post-operative survival and ENO1 immunohistochemical expression using a large number of ADC cases at an identical disease stage. We also examined the potential diagnostic utility of the immunohistochemical expression of ENO1. As described above, high ENO1 expression levels were predominantly detected in TRU cytological subtype ADCs and even in lowgrade tumors (lepidic and papillary histological subtypes). Lepidic and papillary ADCs, which generally show little cytological atypism, are often difficult to discriminate from the reactive hyperplasia of pneumocytes and bronchiolar epithelial cells in small biopsy specimens. The immunohistochemical expression of p53, a conventional diagnostic marker, is uncommon in these low-grade tumors, 23, 24 and, thus, its sensitivity is not satisfactory. The diagnostic utility of ENO1 appears to be superior to that of p53, particularly in TRU-type low-grade ADCs.
In summary, the expression of ENO1 was identified as a common event in lung ADCs. An immunohistochemical examination of ENO1 may have potential utility in the histopathological detection of lung ADC cells in small biopsy specimens.
